Crescent Enterprises Invests $10 Million to Support Cancer Treatment Development with CrossBridge Bio

Crescent Enterprises, the investment arm of Crescent Group, has announced its participation in a $10 million funding round for CrossBridge Bio, a biotechnology company focused on developing innovative treatments. This round was led by TMC Venture, with contributions from Portal Innovations, Alexandria Ventures, and several early-stage investors.

Supporting Cancer Treatment Development with Dual Payload Technology

This funding will be used to support the development of CrossBridge Bio’s CBB-120 drug, a potential treatment for solid tumors. The funding will also enhance the company’s dual payload ADC (antibody-drug conjugate) technology, which provides an innovative solution by delivering treatments directly to cancer cells, minimizing unwanted side effects and boosting treatment efficacy.

Additionally, this funding aims to conduct toxicity studies on CBB-120, a preparatory step toward clinical development, according to Dr. Michael Torres, the company’s CEO.

Crescent Enterprises and Its Global Investment Expansion

Crescent Enterprises, which has invested over $500 million in more than 50 companies worldwide, focuses on fast-growing companies in the fields of technology and life sciences, with a special interest in microbiome-based treatments. These technologies aim to improve human health by interacting with beneficial microorganisms in the body.

Read Also: Umm Al Quwain Launches SOUL Incubator to Boost Innovation and Growth